WO2018078049A1

WO2018078049A1 - Aldosterone synthase inhibitor

Info

Publication number: WO2018078049A1
Application number: PCT/EP2017/077511
Authority: WO
Inventors: Christoph Schumacher; Walter Fuhrer; Ronald Edward Steele
Original assignee: Damian Pharma Ag
Priority date: 2016-10-27
Filing date: 2017-10-26
Publication date: 2018-05-03

Abstract

The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Description

ALDOSTERONE SYNTHASE INHIBITOR

The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazo[l,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders including in premenopausal women and pediatric patients, as well as processes for preparing said inventive compounds.

RELATED ART

Aldosterone synthase (CYP11B2) inhibition has emerged as a new option for the treatment of hypertension, heart failure and renal disorders, in addition to mineralocorticoid receptor (MR) blockade. The aim is to decrease aldosterone concentrations in both plasma and tissues, thereby decreasing MR-dependent and MR- independent effects in the cardiac, vascular and renal target organs. Aldosterone is produced in the zona glomerulosa of the adrenal gland by the enzymatic action of aldosterone synthase (CYP11B2) on deoxycorticosterone (M. Azizi et al., Nephrol Dial Transplant (2013) 28: 36-43).

Initial attempts to inhibit aldosterone synthesis involved the use of various non-selective inhibitors of steroidogenesis but the same was a major safety concern. The concept of targeted pharmacological approach to the specific inhibition of aldosterone synthesis was initiated by the discovery that fadrozole hydrochloride (CGS16949A, INN: Fadrozole; US 4,617,307; US 4,728,645; US 5,098,911), known as a non-steroidal aromatase inhibitor effective for advanced breast cancer treatment, affected aldosterone levels. Subsequent preclinical studies demonstrated that the R-enantiomer (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine chloride is a potent inhibitor of CYP11B2 while the S- enantiomer is responsible for the strong and potent aromatase (CYP19) inhibiting activity of CGS16949A (J. Menard et al, J Hypertens (2006) 24:993; Fiebeler et al, Circulation (2005) 111 :3078-94; Furet et al, J Med Chem (1993) 36: 1393-1400; US 5,057,521).

On the other hand, and despite its early discovery, clinical development of (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine chloride in humans has never been reported and neither a commercially viable synthesis nor a satisfying chiral purity has been disclosed (US 4,889,861). In addition, (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine chloride has been found to be highly hygroscopic (Browne LJ et al, J Med Chem (1991) 34:725-36; Furet et al, J Med Chem (1993) 36: 1393- 1400; US 4,889,861).

The chiral purity of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine chloride is in particular of importance in light of the strong and potent aromatase inhibiting activity of the corresponding (S) enantiomer since extensive evaluation of aromatase inhibitors in clinical trials has revealed numerous deleterious consequences of aromatase inhibition. Thus, a systematic review and meta-analysis consisting of seven trials in 30,023 postmenopausal women with breast cancer and treated with aromatase inhibitors revealed significant increases in the occurrence of bone fractures and cardiovascular disease (Amir et al, J Natl Cancer Inst (2011) 103: 1299-1309). Furthermore, the longer the duration of aromatase inhibition, the stronger the association with cardiovascular disease and bone fractures. In addition, in premenopausal women i.e. in women of child bearing potential, exposure to aromatase inhibition may lead to reproduction disorders and in lactating women, newborns may be exposed to aromatase-inhibiting compounds via secretion into the breast milk. Further, in pediatric patients aromatase inhibition may lead to developmental disorders. Thus, the need for a very high purity and avoidance of contaminants and impurities of such drugs, which are usually applied for a long period of time or even for lifetime, is evident.

Moreover, and beside the required very high chiral purity and the avoidance of aromatase inhibition as an adverse effect, solubility in water and stability including enantiomeric stability over an extended period of time in order to exclude any conversion to aromatase-inhibiting moieties, as well as the processability of such a drug, particularly into forms of administration suitable of oral administration such as tablets, are further combined prerequisites for a pharmaceutical preparation of such a drug.

SUMMARY OF THE INVENTION

The inventors have now surprisingly provided (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine of formula (I) with an unprecedented degree of chiral purity i.e., enantiomeric excess (ee), typically and preferably having an ee of the (R) form higher than or equal to 97%, further preferably even with an ee of the (R) form higher than or equal to 99% or even higher than or equal to 99.5%. Moreover, the inventors have further surprisingly found that the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine, and in particular (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, is non-hygroscopic and stable over an extended period of time, in particular with respect to purity, water content as well as enantiomeric purity. Furthermore and importantly, the inventors have surprisingly found that the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine, and in particular (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate is crystalline in one stable form. In addition, the inventive compounds furthermore possess a decreased and very low aromatase activity, and consequently an increased and very high aldosterone synthase activity, which makes the inventive compounds very suitable as candidates for clinical development in humans, in particular for premenopausal women and pediatric patients. The very low aromatase activity is believed to be even a prerequisite for clinical development and registered use as a medicament to treat diseases and disorders associated with aldosterone overexposure, in particular for premenopausal women, and thus women of child bearing potential, and pediatric patients. The latter is in particular true since and although the amount of aromatase and the percentage conversion of androgen to estrogen may be quantitatively small in extra-gonadal tissues, often being below 1% in any tissue, the effects in terms of hormonal action still may be great (Blakemore and Naftolin, Physiology (2016) 31 :258-269). Thus, the inventive compounds provide for the possibility of life-time treatment of disorders negatively affected by aldosterone production due to minimizing the contamination and negative and unwanted effects caused by the potent aromatase inhibiting (S)-enantiomer.

Accordingly, in a first aspect, the present invention provides for a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine of formula (I) and a pharmaceutically acceptable salt thereof, wherein said compound has an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%>, e.g. 99.9%.

In particular, and in a second aspect, the present invention provides for (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, typically and preferably having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%, e.g. 99.9%) and which has been surprisingly found to be non-hygroscopic and stable over an extended period of time, and hereby in particular with respect to purity, water content and chiral purity. This in particular important since hygroscopicity typically affects negatively the stability of the active pharmaceutical ingredient. Furthermore and importantly, the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine, and in particular (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate is crystalline in one stable form. Unstable polymorphic forms typically affect negatively pharmaceutical efficacy properties.

Furthermore, the present invention provides in further aspects for ( ?)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine as well as the phosphate salt thereof, preferably the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, typically and preferably having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%>, e.g. 99.9%, for use as a medicament and for use in a method of the treatment of a disease or disorder in humans including women of child bearing potential and pediatric patients, in which aldosterone over-exposure contributes to the deleterious effects of said disease or disorder, wherein said disease or disorder is typically and preferably selected from primary and secondary hyperaldosteronism, heart failure, chronic renal failure, hypertension, restenosis, obesity, nephropathy, post-myocardial infarction, renal fibrosis, and coronary heart disease; and wherein further preferably said disease or disorder is selected from primary and secondary hyperaldosteronism. Further preferably, said method is in particular suited for use in humans including preferably for women of child bearing potential and pediatric patients.

The achieved inventive chiral resolution and synthesis of ( ?)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazo[l,5-a]pyridine and ( ?)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate in such a high chiral purity allows now the preparation of pharmaceutical compositions for suppression of aldosterone, typically and preferably by inhibiting the rate limiting enzyme in aldosterone synthesis, namely aldosterone synthase (CYP11B2), with least possible unwanted contaminating aromatase activity. The typical need for life-time treatment of said diseases and disorders reinforces the advantages of the present invention in minimizing the contamination of the beneficial aldosterone synthase inhibiting (i?)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine or a pharmaceutically acceptable salt thereof, and hereby in particular the phosphate salt thereof, and further preferably the (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, from the potent aromatase inhibiting (5)-(-)-enantiomer. As presented in Example 8, Tables 10 and 11, the inventive phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5- ajpyridine, preferably the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate, inhibits aldosterone production (aldosterone synthase activity) and estradiol production (aromatase activity) by NCI-H295R adrenal cells with IC₅o's of 8.1 nM and 5760 nM, respectively; thus demonstrating a more than 700-fold greater inhibition of aldosterone synthase activity as compared to aromatase activity evidencing a highly beneficial safety profile for the inventive phosphate salt of (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazo[l,5-a]pyridine, and further the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate. Thus, the present invention is in particular suited for application in humans, in particular for premenopausal women and pediatric patients. The very low aromatase activity is believed to be even a prerequisite for clinical development and use as a medicament for aldosterone-associated diseases and disorders, in particular for premenopausal women, and thus women of child bearing potential, and pediatric patients.

The inventors have found that (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine prepared by the process of the invention, as well as its phosphate salt, in particular the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, exhibit an unprecedented low inhibitory activity for aromatase. Accordingly, in a further aspect, the present invention provides for (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine or a pharmaceutically acceptable salt thereof, in particular the phosphate salt thereof, more preferably the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, having an IC₅₀ value for aromatase higher than or equal to 700 nM determined by the cell-free human recombinant aromatase enzyme assay described in Example 8, in which the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazo[l,5-a]pyridine, preferably the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, was found to inhibit aromatase activity with an IC₅₀ of 1640 nM.

Moreover, the inventors have found that (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine prepared by the process of the invention, as well as its phosphate salt, preferably the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate, exhibit an unprecedented high inhibitory activity for aldosterone synthase. Accordingly, in a further aspect, the present invention provides for a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine and a pharmaceutically acceptable salt thereof, in particular the phosphate salt thereof, more preferably the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, wherein said compound inhibits aldosterone synthase in the NCI- H295R adrenal cell assay described in Example 8 with an IC₅₀ of 100 nM or less.

In a further aspect, the present invention provides for a process for preparing a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine and a pharmaceutically acceptable salt thereof characterized by enantioselective crystallization of the (-)-0,0'-dibenzoyl-L-tartaric acid salt of (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazo[l,5-a]pyridine, and wherein very preferably said pharmaceutically acceptable salt is the dihydrogen phosphate thereof.

In a further aspect, the present invention provides for a compound selected from (R)-

(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine and a pharmaceutically acceptable salt thereof, wherein said compound has a specific optical rotation [α]ο²⁰ (CH₃CN:H₂0 1 : 1 (v/v)), [a]_D ²⁰ (ethanol) or [a]_D ²⁵ (ethanol), preferably [a]_D ²⁰ (CH₃CN:H₂0 1 : 1 (v/v)), of at least +95°, preferably of at least +96°, more preferably of at least +97°, even more preferably of at least +98°, and wherein preferably said compound is (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, and wherein further preferably said compound inhibits aromatase activity in the cell-free human recombinant aromatase enzyme assay described in Example 8 with an IC₅₀ of 700 nM or more, preferably 1000 nM or more, and more preferably 1500 nM or more; and wherein again further preferably said compound inhibits aldosterone synthase in the NCI-H295R adrenal cell assay described in Example 8 with an IC₅₀ of 100 nM or less, preferably 50 nM or less, and more preferably 10 nM or less. In a very preferred embodiment, said compound is (R)- (+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate and has a specific optical rotation [α]ο²⁰ (CH₃CN:H₂0 1 : 1 (v/v)) of at least +95°, preferably of at least +96°, more preferably of at least +97°, even more preferably of at least +98°, and wherein preferably said compound inhibits aromatase activity in the cell-free human recombinant aromatase enzyme assay described in Example 8 with an IC₅₀ of 700 nM or more, preferably 1000 nM or more, and more preferably 1500 nM or more; and wherein further preferably said compound inhibits aldosterone synthase in the NCI-H295R adrenal cell assay described in Example 8 with an IC₅₀ of 100 nM or less, preferably 50 nM or less, and more preferably 10 nM or less.

In a further aspect, the present invention provides for a compound selected from (R)- (+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine and a pharmaceutically acceptable salt thereof, wherein said compound has a specific optical rotation [α]ο²⁰ (CH₃CN:H₂0 1 : 1 (v/v)), [a]_D ²⁰ (ethanol) or [a]_D ²⁵ (ethanol), preferably [a]_D ²⁰ (CH₃CN:H₂0 1 : 1 (v/v)), of at least +95°, preferably of at least +96°, more preferably of at least +97°, even more preferably of at least +98°, and wherein preferably said compound is (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, and wherein further preferably said compound has a selectivity for aldosterone synthase over aromatase of 50 or more, preferably 100 or more, most preferably 700 or more; wherein said selectivity is determined by the ratio of the IC₅₀ values for inhibition of aromatase and aldosterone synthase; wherein the IC₅₀ values for inhibition of aromatase and aldosterone synthase are both measured, preferably concomitantly, in the NCI-H295R adrenal cell assay described in Example 8. In a very preferred embodiment, said compound is (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate and has a specific optical rotation [α]ο²⁰ (CH₃CN:H₂0 1 :1 (v/v)) of at least +95°, preferably of at least +96°, more preferably of at least +97°, even more preferably of at least +98°, and wherein preferably said compound has a selectivity for aldosterone synthase over aromatase of 50 or more, preferably 100 or more, most preferably 700 or more; wherein said selectivity is determined by the ratio of the IC₅₀ values for inhibition of aromatase and aldosterone synthase; wherein the IC₅₀ values for inhibition of aldosterone synthase and aromatase are both measured, preferably concomitantly, in the NCI-H295R adrenal cell assay described in Example 8.

(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine and a pharmaceutically acceptable salt thereof, wherein said compound inhibits aromatase activity in the cell-free human recombinant aromatase enzyme assay described in Example 8 with an IC₅₀ of 700 nM or more, preferably 1000 nM or more, and more preferably 1500 nM or more; and wherein preferably said compound has an enantiomeric excess of the (R) form higher than or equal to 97%, and wherein further preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate.

In a further aspect, the present invention provides for a compound selected from (R)- (+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine and a pharmaceutically acceptable salt thereof, wherein said compound inhibits aldosterone synthase in the NCI- H295R adrenal cell assay described in Example 8 with an IC₅₀ of 100 nM or less, preferably 50 nM or less, and more preferably 10 nM or less; and wherein preferably said compound has an enantiomeric excess of the (R) form higher than or equal to 97%, and wherein further preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate.

In a further aspect, the present invention provides for a compound selected from (R)- (+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine and a pharmaceutically acceptable salt thereof, wherein said compound has a selectivity for aldosterone synthase over aromatase of 50 or more, preferably 100 or more, most preferably 700 or more; wherein said selectivity is determined by the ratio of the IC₅₀ values for inhibition of aromatase and aldosterone synthase; wherein the IC₅₀ values for inhibition of aldosterone synthase and aromatase are both measured, preferably concomitantly, in the NCI-H295R adrenal cell assay described in Example 8; and wherein preferably said compound has an enantiomeric excess of the (R) form higher than or equal to 97%, and wherein further preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate.

DESCRIPTION OF FIGURES

FIG. 1 : X-ray powder diffraction (XRPD) diffractogram of (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate. The Y-axis of the diffractogram records the intensity in counts per second whereas the X-axis the degrees 2- theta.

FIG. 2: Thermal gravimetric analysis (TGA)/differential scanning calorimetry (DSC) of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate. The upper panel shows a TGA thermogram of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate. The lower panel shows a DSC thermogram of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate. The thermogram indicates a mass loss of 1.4% up to a temperature of 225°C (upper panel) which is beyond the melting point of 189°C (lower panel). The thermogram indicates a melting point with an onset at 188 °C and peaking at 189°C.

FIG. 3: Chiral purity of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate determined by high pressure liquid chromatography (HPLC). The chromatogram demonstrates an enantiomeric excess of the R-(+) enantiomer (retention time 14.459 min) of higher than 99.9% ee (retention time of the S-(-)-enantiomer: 9.814 min).

FIG. 4: Dynamic vapor sorption (DVS) isotherm plot of (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate (overlay of two sorption/desorption cycles).

The dynamic isotherm plot shows a mass increase, respectively hygroscopicity of up to 1%.

FIG. 5: Dynamic vapor sorption (DVS) mass plot change of (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate (dotted curve: relative change in mass; dashed curve: target relative humidity (RH)). The mass plot indicates a reversible water uptake of up to 1%.

FIG. 6: X-ray powder diffraction (XRPD) diffractograms of (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate measured before (upper pattern) and after (lower pattern) DVS cycles. The overlayed diffractograms indicate that DVS treatment does not affect the reflection patterns respectively the crystal form.

FIG. 7: Crystal structure and absolute configuration of (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate determined by single crystal X-ray analysis. The single X-ray determination confirms the R-(+)-configuration on carbon 5.

DETAILED DESCRIPTION OF THE INVENTION

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs.

The term "about" where used means especially ±10%, ±5%> or ±3%> (referring to the given numeric value, respectively), if not indicated otherwise. In each of the invention embodiments, "about" can be deleted. The term "chiral purity" as used herein is defined by the enantiomeric excess (ee) as determined by chiral HPLC (see Examples for details) and calculated by the equation:

ee = (A_R - A_S)/(A_R + A_s) ^χ 100%,

wherein A_R is the area of the (i?)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5- ajpyridine peak in the HPLC chromatogram of the sample solution and As is the area of the (5)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine peak in the HPLC chromatogram of the sample solution.

The term "pharmaceutically acceptable salt" as used herein refers to a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include acid addition salts formed with inorganic acids or organic acids known to the skilled person in the art (P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor); Handbook of Pharmaceutical Salts: Properties, Selection, and Use, 2nd Revised Edition, March 2011, Wiley- VCH, ISBN: 978-3-90639-051-2). A particularly preferred pharmaceutically acceptable salt in the present invention is an acid addition salt formed with phosphoric acid, i.e. a dihydrogen phosphate.

The term "phosphate salt" as used in the present application refers to compounds comprising (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine in its protonated form, i.e. the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine cation and further comprising anions derived from phosphoric acid, wherein said anions are typically and preferably selected from dihydrogen phosphate [H₂P0₄] and hydrogen phosphate [HP0₄]^2". Preferably, the term "phosphate salt" as used in the present application refers to the compound of formula (I) dihydrogen phosphate, that is, wherein the compound of formula (I) is protonated once and the counterion is [H₂P0₄] (see FIG. 7 for single crystal X-ray structure) and, thus, the stoichiometry of mono-protonated (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine to dihydrogen phosphate is 1 : 1. The latter compound is referred herein as (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate.

The term "aromatase" refers to CYP19, a member of the cytochrome P450 superfamily, and is also known as estrogen synthase.

The term "aldosterone synthase" refers to the steroid hydroxylase cytochrome P450 enzyme CYP11B2.

The term "amorphous" as used herein, means a supercooled liquid or a viscous liquid which looks like a solid but does not have a regularly repeating arrangement of molecules that is maintained over a long range and does not have a melting point but rather softens or flows above its glass transition temperature.

The terms "crystalline" and "crystalline purity" as interchangeably used herein and related to the inventive compounds, refer to a solid having a regularly repeating arrangement of molecules or external face planes. Preferably, the terms "crystalline" and "crystalline purity" when referring to (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate comprising (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate refers to the crystalline form I, wherein said crystalline form I is present of at least 60% by total weight, preferably of at least 70% by total weight, further preferably of at least 80% by total weight, again further preferably of at least 90% by total weight, and again further preferably of at least 95% by total weight. Further components may be, for example, amorphous (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate. Crystalline purity may be determined by means of XRPD as described herein. Thus, in a preferred embodiment said XRPD can be determined using the following device, parameters and measuring conditions: Instrument: Bruker AXS D2 PHASER; Irradiation: CuKa (30kV, 10 mA); scan range: 5 to 45° (2 theta value), sample rotation 5 rpm, 0.5s/step, 0.010°/step, 3.0mm detector slit.

The term "crystalline form I" as used herein refers to the (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, wherein said (R)-(+)-5- (p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate has an X-ray powder diffraction pattern comprising the following 2Θ values measured using CuKa radiation: 19.504; 21.919 and 24.159, wherein each peak may vary by ± 1 or preferably by ± 0.5, or further preferably by ± 0.2 degrees. In a preferred embodiment, "crystalline form I" as used herein refers to the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate, wherein said (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate has an X-ray powder diffraction pattern comprising the following 2Θ values measured using CuKa radiation, 19.504; 21.919 and 24.159, wherein each peak may vary by ± 1 or preferably by ± 0.5, or further preferably by ± 0.2 degrees. In a further preferred embodiment, "crystalline form I" as used herein refers to the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, wherein said (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate has an X-ray powder diffraction pattern comprising the following 2Θ values measured using CuKa radiation, 19.504; 21.919 and 24.159, wherein each peak may vary by ± 0.5, or preferably by ± 0.2 degrees. In again a further preferred embodiment, the term "crystalline form I" as used herein refers to the (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, wherein said (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate has an X-ray powder diffraction pattern comprising the following 2Θ values measured using CuKa radiation, 19.504; 21.919 and 24.159, wherein each peak may vary by ± 0.2 degrees. In another preferred embodiment, "crystalline form I" as used herein refers to the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, wherein said (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate has an X-ray powder diffraction pattern comprising the following 2Θ values measured using CuKa radiation: 19.504; 21.919; 24.159; 16.003; 26.101; 27.168; 27.542 and 29.029, wherein each peak may vary by ± 1 or preferably by ± 0.5, or further preferably by ± 0.2 degrees. In another preferred embodiment, "crystalline form I" as used herein refers to the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate, wherein said (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate has an X-ray powder diffraction pattern comprising the following 2Θ values measured using CuKa radiation: 19.504; 21.919; 24.159; 16.003; 26.101; 27.168; 27.542 and 29.029, wherein each peak may vary by ± 0.5, or preferably by ± 0.2 degrees.

The term "anhydrous" as used herein refers to a crystalline form which contains less than 3%, preferably less than 2.5%, more preferably less than 2%, more preferably less than 1.5%, most preferably less than 1 % water of hydration.

The term "non-hygroscopic" means the ability by the inventive pharmaceutically acceptable salts of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine, and in particular of the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine, more preferably the (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, when they occur as powders or granules, to withstand exposure to the water vapor of an ambient atmosphere for 24 hours, weeks, months or years as a premise for commercial use without giving rise to adverse phenomena of aggregating, agglomerating, absorbing water, or deliquescing. Typically and preferably, the term "non- hygroscopic" as used herein and referring to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine, and preferably when referring to the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, means that on storage in the open under normal ambient conditions, typically and preferably at 20-25 °C and a relative humidity of between 20% and 80%, preferably between 30%> and 60%>, it preserves its consistency as (preferably free-flowing) powder or granules over a period of at least one day, preferably one week, further preferably one month, again further preferably over a period of at least 3 months, and again further preferably for at least 6 months, and again further preferably or at least 1 year or more, in particular, to meet regulatory ICH standards. Further preferably, the term "non- hygroscopic" as used herein and referring to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine, and preferably when referring to the (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, means that on storage in the open under normal ambient conditions, typically and preferably at 20-25 °C and a relative humidity of between 20% and 80%, preferably between 30%> and 60%>, for a period of 24 hours, typically and preferably as determined in Example 5, it shows a weight increase of less than 5%, preferably of less than 3%, further preferably of less than 2%, again further preferably of less than 1%. Again further preferably, the term "non-hygroscopic" as used herein and referring to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine, and preferably when referring to the (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, means that on storage in the open under normal ambient conditions, typically and preferably at room temperature, most preferably at 20-25 °C and at a relative humidity of between 20% and 80%, preferably between 30% and 60%, for a period of 24 hours, typically and preferably as determined in Example 5, said phosphate salt, preferably said (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate shows a water uptake of less than 5% (wt/wt), preferably of less than 3% (wt/wt), further preferably of less than 2% (wt/wt), again further preferably of less than 1% (wt/wt). Alternatively preferred, the term "non- hygroscopic" as used herein and referring to the phosphate salt of (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine, and preferably when referring to the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, means that on storage in the open under normal ambient conditions, typically and preferably at 25 °C and a relative humidity of between of about 60%, for a period of 24 hours, preferably for a period of one month, further preferably for a period of at least 3 months, and again further preferably for at least 6 months, and again further preferably or at least 1 year, typically and preferably as determined in Example 9, the water content is less than 0.5 w/w%, preferably less than 0.4 w/w%, and further preferably equal or less than 0.3 w/w%.

The term "pharmaceutically acceptable excipient" as used herein includes any physiologically inert additive that is routinely used in pharmaceutical dosage forms. Pharmaceutically acceptable excipients are selected from the group comprising binders, diluents, carriers, lubricants, glidants, coating additives or combinations thereof.

The term "solubility" as used herein refers to simplified descriptive solubilities (e.g. in water) in accordance with the U.S. Pharmacopoeia, Chapter "General Notices", § 5.30 "Description and Solubility" (and as defined below):

Parts of Solvent Required

Descriptive Term for Ϊ Part of Solute

Very soluble Less than 1

Freely soluble From J to 10

Soluble From 10 to 30

Sparingly soluble From 30 to 100

Slightly soluble From 100 to 1 ,000

Very slightly soluble From 1 ,000 to 10,000

Practically Insoluble, or Greater than or equal to

Insoluble 10,000

The term "woman of childbearing potential" as used herein refers to a premenopausal female capable of becoming pregnant.

The term "pediatric patient" as used herein refers to patient in the age category 0-18, preferably 0-16 years and include preterm and term newborn infants (0-27 days), infants and toddlers (28 days to 23 months), children (2-11 years) and adolescents (2 to 16/18 years).

Accordingly, in one embodiment, there is provided a compound selected from (R)-(+)- 5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine of formula (I) and a pharmaceutically acceptable salt thereof, in particular (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, having a solubility in water of more than 50% vol/vol.

The expression "IC₅₀" refers to the half maximal inhibitory concentration as commonly known in the art. The IC₅₀ for aromatase is determined by the cell-free human recombinant aromatase assay described in Example 8. The IC₅₀ for aldosterone synthase is determined by the human NCI-H295R cell assay described in Example 8. When referring to "selectivity for aldosterone synthase over aromatase", the following ratio is meant:

IC50 for aromatase

selectivity =

IC50 for aldosterone synthase

wherein both the IC₅₀ for aldosterone synthase and the IC₅₀ for aromatase are determined, preferably concomitantly, by the human NCI-H295R cell assay described in Example 8.

As outlined above, the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine, preferably the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, inhibits aldosterone production (aldosterone synthase activity) and estradiol production (aromatase activity) by NCI-H295R adrenal cells with ICso's of 8.1 nM and 5760 nM, respectively (Example 8, Tables 10 and 11); thus demonstrating a selectivity of about 700 for aldosterone synthase over aromatase.

As used herein, the term "a disorder" or "a disease" refers to any derangement or abnormality of function; a morbid physical or mental state. See Dorland's Illustrated Medical Dictionary (VSIB. Saunders Co. 27th ed. 1988).

As used herein, the expression "disease or disorder in which aldosterone over-exposure contributes to the deleterious effects of said disease or disorder" preferably refers to a disease and disorder which is due to the abnormal or inappropriate activity/expression of aldosterone synthase and the biological activity or process which is associated with the abnormal or inappropriate expression of aldosterone synthase. Typical examples of diseases or disorders that are due to abnormal or inappropriate activity/expression of aldosterone synthase are primary and secondary hyperaldosteronism, heart failure, chronic renal failure, hypertension, restenosis, obesity, nephropathy, post-myocardial infarction, renal fibrosis, and coronary heart disease.

As used herein, the term "abnormal activity of aldosterone synthase" refers to an activity of aldosterone synthase which differs from the activity of the wild-type or native gene or protein, or which differs from the activity of the gene or protein in a healthy subject. The abnormal activity can be stronger or weaker than the normal activity.

As used herein, the term "inappropriate activity of aldosterone synthase" refers to the activity of aldosterone synthase of the wild-type or native gene or protein or to the activity of the gene or protein in a healthy subject, which is considered as appropriate in a healthy subject, but the same said activity is considered inappropriate for a diseased subject, i.e. said activity is too strong or too weak for a diseased subject.

As used herein, the term "treating" or "treatment" of any disease or disorder refers to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).

As used herein, the term "specific optical rotation" refers to the specific optical rotation of a solution of the respective compound in a solvent, wherein said solvent is typically and preferably ethanol or CH₃CN:H₂0 1 : 1 (v/v), further preferably CH₃CN:H₂0 1 : 1 (v/v), and wherein said specific optical rotation is calculated by the formula: 100 x a / (1 x c), wherein a = observed rotation in degrees; 1 = cell path length in decimeters; c = concentration in grams per 100 ml, and wherein the measurement is performed at the sodium D line (i.e. 589.3 nm) at room temperature, typically and preferably at either 20 °C or 25 °C. The term "specific optical

20 25 20 25

rotation" is abbreviated as [α]ο or [α]ο . Typically, for [α]ο or [α]ο , either the sign of the rotation (+ or -) and its actual value is indicated herein or [α]ο²⁰ or [a]o²⁵ is provided by way of its sign of the rotation (+ or -) and its actual value indicated in degrees (°). The complete unit as determined above (deg dm^"1 cm³ g^"1) is typically omitted for the sake of clarity.

In a first aspect, the present invention provides for a compound selected from (R)-(+)-5- (p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine of formula (I) and a pharmaceutically acceptable salt thereof having an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%>, e.g. 99.9%.

In particular, and in a second aspect, the present invention provides for (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l ,5-a]pyridine dihydrogen phosphate, typically and preferably having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%, e.g. 99.9%) and which has been surprisingly found to be non-hygroscopic and stable over an extended period of time, in particular with respect to purity, water content and chiral purity. Furthermore and importantly, the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l ,5-a]pyridine, and in particular (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l ,5-a]pyridine dihydrogen phosphate is crystalline in one stable form, typically and preferably in said crystalline form I.

The water uptake of the inventive (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l ,5-a]pyridine dihydrogen phosphate as measured by Dynamic Vapour Sorption studies is less than 1% at greater than 90% humidity (Fig. 4) and in addition the water uptake is reversible (Fig. 5). Furthermore, the mass loss upon heating up to a temperature of 225 °C was only 1.4% (Fig. 2). In conclusion, the inventive phosphate salt, preferably the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l ,5-a]pyridine dihydrogen phosphate, is not hygroscopic. As a consequence, the inventive (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l ,5-a]pyridine dihydrogen phosphate can be stored in bulk in customary pharmaceutical containment vessels at ambient conditions. Moreover, the inventive (i?)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l ,5- ajpyridine dihydrogen phosphate has been found to be highly crystalline and having a high level of crystalline purity. Furthermore, and surprisingly the inventive (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate with the described exceptional chiral purity is present in one single crystalline form with a defined x- ray structure and R-(+)- absolute configuration on carbon 5, its chiral center (Fig. 1 and Table l; Fig. 7).

Multiple crystalline forms - so called polymorphs - complicate the manufacturing of pharmaceutical preparations because such forms can interconvert requiring additional provisions to prevent such interconversion. Different polymorphs behave differently in the formulation of pharmaceutical products; they can affect micronization, tablet formation, solubility and also bioavailability. Since even the smallest compound may have hundreds of thousands of possible arrangements of its molecules in a solid crystal, predicting crystal structures and their properties are a great scientific challenge and it is not possible to know a priori whether polymorphism will actually occur for a given molecule. Polymorphism is thus a serious concern when seeking to provide safe and efficacious forms of a drug. Despite this, the inventors have discovered that the crystalline form I of (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate is physically stable, i.e. polymorphism was not observed (Example 6, Table 8; Example 7, Table 9 and Fig. 6, Example 9) and can be obtained predictably and reliably (Example 3, step 4). Furthermore, XRPD analysis of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate (Fig. 1 and Table 1) showed that the substance was essentially free of amorphous material (i.e. amorphous material was not detectable). XRPD was performed, if not described otherwise, as described in the Examples section.

Thus, in one embodiment, the present invention provides crystalline (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, preferably anhydrous crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate, more preferably anhydrous crystalline (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%), again more preferably higher than or equal to 99.8%>, e.g. 99.9%.

The crystals of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate (crystalline form I) are characterized by XRPD (Fig. 1) with the following angles, lattice spacings (d values) and relative line intensities (intensity) of their X-ray powder pattern (Table 1). Table 1. XRPD Peak list of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate crystalline form I

Index 2Θ Angle d Value Relative Intensity

1 6.023129 14.6619 0.1166064

2 9.969034 8.865584 0.04637039

3 11.26224 7.850313 0.01466121

4 11.22848 7.873846 0.01766241

5 11.96566 7.390353 0.07938031

6 12.77761 6.922504 0.07618304

7 13.79347 6.414874 0.06721209

8 14.39314 6.148929 0.08399912

9 15.3394 5.771677 0.09292314

10 16.00317 5.533746 0.2509092

11 16.27337 5.442465 0.1271836

12 17.07502 5.188714 0.01814438

13 17.27593 5.128821 0.06430446

14 17.9904 4.926713 0.09392752

15 18.38238 4.822532 0.07743008

16 18.65471 4.752738 0.07315308

17 18.96096 4.676658 0.07685736

18 19.14281 4.632641 0.1232251

19 19.504 4.547657 0.9732185

20 20.01265 4.433205 0.1459729

21 20.58808 4.310579 0.06427268

22 20.43302 4.34294 0.03934043

23 20.72112 4.283203 0.1308791

24 21.12683 4.201858 0.09223638

25 21.91906 4.051746 1.00000000

26 22.59202 3.932552 0.0988786

27 24.44788 3.63807 0.1554819

28 24.15917 3.680887 0.6751482

29 24.48119 3.633195 0.1650803

30 25.70071 3.463495 0.05630966 31 26.10094 3.411286 0.1425888

32 26.58127 3.350723 0.02198978

33 27.16767 3.279716 0.1315578

34 27.54165 3.236025 0.09750613

35 27.71408 3.216282 0.01282637

36 28.27603 3.153627 0.01739924

37 28.09725 3.173285 0.004438166

38 28.54909 3.124082 0.02253263

39 29.02939 3.073475 0.2474836

40 29.71314 3.004288 0.01214569

41 30.07578 2.968884 0.04296284

42 30.68808 2.911028 0.01120924

43 30.92867 2.88893 0.02964231

44 31.6379 2.825768 0.0454447

45 32.27005 2.771842 0.01273681

46 32.79806 2.728414 0.01504905

47 33.20638 2.695791 0.04151051

48 33.23304 2.693689 0.04147112

49 33.65808 2.660638 0.009918388

50 34.41793 2.603618 0.02669827

51 34.35512 2.608234 0.03452484

52 35.02142 2.560122 0.01117852

53 35.06671 2.556919 0.01513675

54 35.68978 2.513696 0.03497554

55 35.93622 2.497021 0.01164656

56 36.50305 2.459537 0.004599076

57 36.56591 2.455453 0.004500904

58 36.92023 2.432697 0.01221618

59 37.14021 2.418792 0.01601023

60 37.89624 2.372257 0.03661312

61 39.60815 2.27358 0.01607032

62 40.22464 2.240145 0.004137916 In one embodiment there is provided a crystalline form I of (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, characterized by an X- ray powder diffraction pattern comprising the following 2Θ values measured as described in the Examples section: 19.504; 21.919 and 24.159. In one embodiment there is provided a crystalline form I of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, characterized by an X-ray powder diffraction pattern comprising the following 2Θ values measured as described in the Examples section: 19.504; 21.919 and 24.159, wherein each peak may vary by ± 1 or preferably by ± 0.5, or further preferably by ± 0.2 degrees. In a preferred embodiment, said X-ray powder diffraction pattern further comprises the following 2Θ values: 16.003; 26.101; 27.168; 27.542 and 29.029. In a preferred embodiment, said X-ray powder diffraction pattern further comprises the following 2Θ values: 16.003; 26.101; 27.168; 27.542 and 29.029, wherein each peak may vary by ± 1 or preferably by ± 0.5, or further preferably by ± 0.2 degrees. In a particularly preferred embodiment, there is provided a crystalline form I of (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, characterized by an X-ray powder diffraction pattern comprising at least one, more preferably 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or all of the following 2Θ values: 6.023129; 9.969034; 11.26224; 11.22848; 11.96566; 12.77761; 13.79347; 14.39314; 15.3394; 16.00317; 16.27337; 17.07502; 17.27593; 17.9904; 18.38238; 18.65471; 18.96096; 19.14281; 19.504; 20.01265; 20.58808; 20.43302; 20.72112; 21.12683; 21.91906; 22.59202; 24.44788; 24.15917; 24.48119; 25.70071; 26.10094; 26.58127; 27.16767; 27.54165; 27.71408; 28.27603; 28.09725; 28.54909; 29.02939; 29.71314; 30.07578; 30.68808; 30.92867; 31.6379; 32.27005; 32.79806; 33.20638; 33.23304; 33.65808; 34.41793; 34.35512; 35.02142; 35.06671; 35.68978; 35.93622; 36.50305; 36.56591; 36.92023; 37.14021; 39.60815; 37.89624 and 40.22464. In another particularly preferred embodiment, there is provided a crystalline form I of (R)-(+)-5- (p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, characterized by an X-ray powder diffraction pattern comprising at least one, more preferably 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or all of the following 2Θ values: 6.023129; 9.969034; 11.26224; 11.22848; 11.96566; 12.77761; 13.79347; 14.39314; 15.3394; 16.00317; 16.27337; 17.07502; 17.27593; 17.9904; 18.38238; 18.65471; 18.96096; 19.14281; 19.504; 20.01265; 20.58808; 20.43302; 20.72112; 21.12683; 21.91906; 22.59202; 24.44788; 24.15917; 24.48119; 25.70071; 26.10094; 26.58127; 27.16767; 27.54165; 27.71408; 28.27603; 28.09725; 28.54909; 29.02939; 29.71314; 30.07578; 30.68808; 30.92867; 31.6379; 32.27005; 32.79806; 33.20638; 33.23304; 33.65808; 34.41793; 34.35512; 35.02142; 35.06671; 35.68978; 35.93622; 36.50305; 36.56591; 36.92023; 37.14021; 39.60815; 37.89624 and 40.22464, wherein each peak may vary by ± 1 or preferably by ± 0.5, or further preferably by ± 0.2 degrees. In another particularly preferred embodiment, there is provided a crystalline form I of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, characterized by an X-ray powder diffraction pattern comprising at least one, more preferably 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or all of the following 2Θ values: 6.023129; 9.969034; 11.26224; 11.22848; 11.96566; 12.77761; 13.79347; 14.39314; 15.3394; 16.00317; 16.27337; 17.07502; 17.27593; 17.9904; 18.38238; 18.65471; 18.96096; 19.14281; 19.504; 20.01265; 20.58808; 20.43302; 20.72112; 21.12683; 21.91906; 22.59202; 24.44788; 24.15917; 24.48119; 25.70071; 26.10094; 26.58127; 27.16767; 27.54165; 27.71408; 28.27603; 28.09725; 28.54909; 29.02939; 29.71314; 30.07578; 30.68808; 30.92867; 31.6379; 32.27005; 32.79806; 33.20638; 33.23304; 33.65808; 34.41793; 34.35512; 35.02142; 35.06671; 35.68978; 35.93622; 36.50305; 36.56591; 36.92023; 37.14021; 39.60815; 37.89624 and 40.22464, wherein each peak may vary by ± 0.5, or preferably by ± 0.2 degrees. In one embodiment, the three largest peaks of crystalline form I in the XRPD diffractogram have a relative intensity of 1 to 0.85 to 0.55, especially of 1 to 0,9 to 0.6, more especially of 1 to 0.95 to 0.65, e.g. of 1 to 0.97 to 0.68 (obtainable by integration of each of the peaks in the XRPD diagrams). In a particular embodiment the largest peak is at a 2-theta (Θ) value of about 21.919 and the second- largest peak is at a 2-theta (Θ) value of about 19.504 and the third- largest peak is at a 2-theta (Θ) value of about 24.159, respectively. In a further particular embodiment the largest peak is at a 2-theta (Θ) value of about 21.919 ± 0.5, or preferably by ± 0.2 degrees, and the second- largest peak is at a 2-theta (Θ) value of about 19.504 ± 0.5, or preferably by ± 0.2 degrees and the third-largest peak is at a 2-theta (Θ) value of about 24.159± 0.5, or preferably by ± 0.2 degrees, respectively. Preferred is the (R)- (+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate showing an XRPD diffractogram as shown in Fig. 1.

It was further surprisingly found that (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate (crystalline form I) has a single sharp and high melting point of 189°C as measured by DSC (Fig. 2), again indicating high physical stability and which is further very beneficial with regards to drug manufacture, storage and processing to pharmaceutical formulations. Accordingly, in one embodiment, there is provided (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate having a melting point of equal or between 184 °C to 193 °C, and wherein preferably said (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate has a melting point of equal or between 188 °C to 190 °C , typically and preferably using thermogravimetry analysis/differential scanning calorimetry (TGA/DSC). In a further embodiment, there is provided (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate having a melting point of 184 °C, 185 °C, 186 °C, 187 °C, 188 °C, 189 °C, 190 °C, 191 °C, 192 °C, 193 °C or 194 °C, most preferably 189 °C. In a further embodiment, there is provided (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate having a melting point of 189±5 °C, 189±2 °C, 189±1 °C or 189±0.5 °C. The melting temperatures herein, if not described otherwise, are obtained by TGA/DSC as described in the Examples section.

In addition, the inventors have found that the solubility of (R)-(+)-5-(p-cyanophenyl)-

5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate (crystalline form I) is low in a number of non-aqueous solvents (Example 6, Table 7) which are thus anti-solvents for the salt, thus making it possible to achieve good precipitation and thus good yields and good purity. On the other hand, crystalline form I is very soluble in water (Example 6, Table 8), which is advantageous for providing oral or parenteral formulations.

The (i?)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate prepared from the enantiomerically pure (i?)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazo[l,5-a]pyridine free base described herein and thus having an ee of >99.9%, was found to have a specific optical rotation ([a]_D ²°) of +98. Γ (CH₃CN:H₂0 1 : 1 (v/v); Example 3).

Accordingly, in one very preferred embodiment and aspect of the present invention, there is provided (i?)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate having a specific optical rotation ([α]ο²⁰) (CH₃CN:H₂0 1 : 1 (v/v)) of at least +94°, preferably of at least +95°, further preferably of at least +96°, more preferably of at least +97°, even more preferably of at least +98°.

In a further embodiment, the present invention provides for (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazo[l,5-a]pyridine having a specific optical rotation [α]ο²⁵ (ethanol) of at least +120°, preferably of at least +121°, further preferably of at least +122°, again further preferably of at least +123°, again further preferably of at least +124°, again further preferably of at least +125°, again further preferably of at least +126°, and again further preferably of at least +127°. In another embodiment, the present invention provides for (R)- (+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine chloride having a specific optical rotation [α]ο²⁰ (ethanol) of at least +95°, preferably of at least +96°, further preferably of at least +97°, more preferably of at least +98°, even more preferably of at least +99°, further preferably of at least +100°, more preferably of at least +101°, even more preferably of at least +102°, and again more preferably of at least +103°, even more preferably of at least +104°.

In a very preferred aspect, the present invention provides (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, preferably crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, more preferably anhydrous crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate.

In again a very preferred embodiment and aspect, the present invention provides (R)- (+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, preferably crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate, more preferably anhydrous crystalline (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%), again more preferably higher than or equal to 99.8%>, e.g. 99.9%.

In again a very preferred embodiment and aspect, the present invention provides crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, preferably anhydrous crystalline (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%>, e.g. 99.9%, and wherein preferably said (R)-(+)-5- (p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate is a crystalline form I of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, wherein said crystalline form I has an X-ray powder diffraction pattern comprising the following 2Θ values measured using CuKa radiation: 19.504; 21.919 and 24.159, wherein each peak may vary by ± 0.5, or preferably by ± 0.2 degrees.

In again a very preferred embodiment and aspect, the present invention provides crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, preferably anhydrous crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%, e.g. 99.9%, and wherein said (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate is a crystalline form I of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, wherein said crystalline form I has an X-ray powder diffraction (XRPD) pattern comprising the following 2Θ values measured using CuKa radiation: 19.504; 21.919 and 24.159, wherein each peak may vary by ± 0.5, or preferably by ± 0.2 degrees, wherein preferably said XRPD can be determined using the following device, parameters and measuring conditions: Instrument: Bruker AXS D2 PHASER; Irradiation: CuKa (30kV, 10 mA); scan range: 5 to 45° (2 theta value), sample rotation 5 rpm, 0.5s/step, 0.010°/step, 3.0mm detector slit.

In again a very preferred embodiment and aspect, the present invention provides crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, preferably anhydrous crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%>, e.g. 99.9%, and wherein said (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate is a crystalline form I of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, wherein said crystalline form I has an X-ray powder diffraction pattern comprising the following 2Θ values measured using CuKa radiation: 19.504; 21.919 and 24.159, wherein each peak may vary by ± 0.5, or preferably by ± 0.2 degrees, said XRPD can be determined using the following device, parameters and measuring conditions: Instrument: Bruker AXS D2 PHASER; Irradiation: CuKa (30kV, 10 mA); scan range: 5 to 45° (2 theta value), sample rotation 5 rpm, 0.5s/step, 0.010°/step, 3.0mm detector slit.

(i?)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate has further been found to be anhydrous (Example 3 and 5). Thus, in one embodiment, the present invention provides for anhydrous (i?)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate. In a particularly preferred embodiment, the present invention provides for anhydrous (i?)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%>, e.g. 99.9%. In a further particularly preferred embodiment, the present invention provides for anhydrous (i?)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate crystalline form I.

In yet a further particularly preferred embodiment, the present invention provides for anhydrous (i?)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate crystalline form I as defined herein, having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%>, e.g. 99.9%.

As outlined above, the inventors have surprisingly found that (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine prepared by the process of the invention (Example 3), as well as its phosphate salt, preferably the (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, exhibit an unprecedented low inhibitory activity for aromatase (Example 8), which is crucial to avoid side effects related to inhibition of aromatase when using the compounds of the invention in methods of treating diseases or disorders related to enhanced aldosterone synthase activity and/or enhanced levels of aldosterone, in particular when used for women of child bearing potential and pediatric patients. Accordingly, in a further aspect, the present invention provides for a compound selected from (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine and a pharmaceutically acceptable salt thereof, in particular the phosphate salt thereof, further preferably the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, wherein said compound inhibits aromatase activity in the cell-free human recombinant aromatase enzyme assay described in Example 8 with an IC₅₀ of 700 nM or more, preferably 750 nM or more, more preferably 800 nM or more, more preferably 850 nM or more, more preferably 900 nM or more, more preferably 950 nM or more, more preferably 1000 nM or more, more preferably 1050 nM or more, more preferably 1100 nM or more, more preferably 1 150 nM or more, more preferably 1200 nM or more, more preferably 1250 nM or more, more preferably 1300 nM or more, more preferably 1350 nM or more, more preferably 1400 nM or more, more preferably 1450 nM or more, more preferably 1500 nM or more, more preferably 1550 nM or more, most preferably at least 1600 nM, e.g. 1610 nM or 1620 nM or 1630 nM or 1640 nM or at least 1650 nM.

In yet a further aspect, the present invention provides for a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine and a pharmaceutically acceptable salt thereof, in particular the phosphate salt thereof, further preferably the (R)-(+)- 5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l ,5-a]pyridine dihydrogen phosphate, wherein said compound inhibits aldosterone synthase in the NCI-H295R adrenal cell assay described in Example 8 with an IC₅₀ of 100 nM or less. In one embodiment, the compounds of the invention inhibit aldosterone synthase in the NCI-H295R adrenal cell assay described in Example 8 with an IC₅₀ of 90 nM or less, 80 nM or less, 70 nM or less, 60 nM or less, 50 nM or less, 40 nM or less, 35 nM or less, 30 nM or less, 25 nM or less, or 20 nM or less; in particular 15 nM or less, e.g., 15 nM, 14 nM, 13 nM, 12 nM, 11 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM or 1 nM or less. In a preferred embodiment, the compounds of the invention inhibit aldosterone synthase in the NCI-H295R adrenal cell assay described in Example 8 with an IC₅₀ of 10 nM or less.

In yet a further aspect, the present invention provides for a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine and a pharmaceutically acceptable salt thereof, wherein said compound has a selectivity for aldosterone synthase over aromatase of 30 or more, preferably 50 or more, more preferably 100 or more, more preferably 150 or more, more preferably 200 or more, more preferably 250 or more, more preferably 300 or more, more preferably 350 or more, more preferably 400 or more, more preferably 450 or more, more preferably 500 or more, more preferably 550 or more, more preferably 600 or more, more preferably 650 or more, most preferably 700 or more, wherein said selectivity is determined by the ratio of the IC₅₀ values for inhibition of aromatase and aldosterone synthase; and wherein the IC₅₀ values for inhibition of aldosterone synthase and aromatase are both measured, preferably concomitantly, in the NCI-H295R adrenal cell assay described in Example 8.

Thus, in again a very preferred embodiment and aspect, the present invention provides crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, preferably anhydrous crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%>, e.g. 99.9%, wherein said (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate is a crystalline form I of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, wherein said crystalline form I has an X-ray powder diffraction pattern comprising the following 2Θ values measured using CuKa radiation: 19.504; 21.919 and 24.159, wherein each peak may vary by ± 0.5, or preferably by ± 0.2 degrees, said XRPD can typically and preferably be determined using the following device, parameters and measuring conditions: Instrument: Bruker AXS D2 PHASER; Irradiation: CuKa (30kV, 10 mA); scan range: 5 to 45° (2 theta value), sample rotation 5 rpm, 0.5s/step, 0.010°/step, 3.0mm detector slit, and wherein said (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate inhibits aromatase activity in the cell-free human recombinant aromatase enzyme assay described in Example 8 with an IC₅₀ of 700 nM or more, preferably 750 nM or more, more preferably 800 nM or more, more preferably 850 nM or more, more preferably 900 nM or more, more preferably 950 nM or more, more preferably 1000 nM or more, more preferably 1050 nM or more, more preferably 1100 nM or more, more preferably 1150 nM or more, more preferably 1200 nM or more, more preferably 1250 nM or more, more preferably 1300 nM or more, more preferably 1350 nM or more, more preferably 1400 nM or more, more preferably 1450 nM or more, more preferably 1500 nM or more, more preferably 1550 nM or more, most preferably at least 1600 nM, e.g. 1610 nM or 1620 nM or 1630 nM or 1640 nM or at least 1650 nM.

In again a very preferred embodiment and aspect, the present invention provides crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, preferably anhydrous crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%>, e.g. 99.9%, wherein said (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate is a crystalline form I of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, wherein said crystalline form I has an X-ray powder diffraction pattern comprising the following 2Θ values measured using CuKa radiation: 19.504; 21.919 and 24.159, wherein each peak may vary by ± 0.5, or preferably by ± 0.2 degrees, said XRPD can typically and preferably be determined using the following device, parameters and measuring conditions: Instrument: Bruker AXS D2 PHASER; Irradiation: CuKa (30kV, 10 mA); scan range: 5 to 45° (2 theta value), sample rotation 5 rpm, 0.5s/step, 0.010°/step, 3.0mm detector slit, and wherein said (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate inhibits aldosterone synthase in the NCI-H295R adrenal cell assay described in Example 8 with an IC₅₀ of 90 nM or less, 80 nM or less, 70 nM or less, 60 nM or less, 50 nM or less, 40 nM or less, 35 nM or less, 30 nM or less, 25 nM or less, or 20 nM or less; in particular 15 nM or less, e.g., 15 nM, 14 nM, 13 nM, 12 nM, 11 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM or 1 nM or less. In a preferred embodiment, the compounds of the invention inhibit aldosterone synthase in the NCI-H295R adrenal cell assay described in Example 8 with an IC₅₀ of 10 nM or less.

In again a very preferred embodiment and aspect, the present invention provides crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, preferably anhydrous crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%>, e.g. 99.9%>, wherein said (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate is a crystalline form I of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, wherein said crystalline form I has an X-ray powder diffraction pattern comprising the following 2Θ values measured using CuKa radiation: 19.504; 21.919 and 24.159, wherein each peak may vary by ± 0.5, or preferably by ± 0.2 degrees, said XRPD can typically and preferably be determined using the following device, parameters and measuring conditions: Instrument: Bruker AXS D2 PHASER; Irradiation: CuKa (30kV, 10 mA); scan range: 5 to 45° (2 theta value), sample rotation 5 rpm, 0.5s/step, 0.010°/step, 3.0mm detector slit, and wherein said (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- ajpyridine dihydrogen phosphate has a selectivity for aldosterone synthase over aromatase of 30 or more, preferably 50 or more, more preferably 100 or more, more preferably 150 or more, more preferably 200 or more, more preferably 250 or more, more preferably 300 or more, more preferably 350 or more, more preferably 400 or more, more preferably 450 or more, more preferably 500 or more, more preferably 550 or more, more preferably 600 or more, more preferably 650 or more, most preferably 700 or more, wherein said selectivity is determined by the ratio of the IC₅₀ values for inhibition of aromatase and aldosterone synthase; and wherein the IC₅₀ values for inhibition of aldosterone synthase and aromatase are both measured, preferably concomitantly, in the NCI-H295R adrenal cell assay described in Example 8.

In one aspect, the present invention provides for ( ?)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%, e.g. 99.9% for use as a medicament.

In a further aspect, the present invention provides for ( ?)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate for use as a medicament, wherein preferably said dihydrogen phosphate has an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%, e.g. 99.9%.

The present invention further provides for ( ?)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine as well as the phosphate salt thereof, preferably the (R)-(+)- 5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l ,5-a]pyridine dihydrogen phosphate, typically and preferably having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%), e.g. 99.9%) for use in a method of the treatment of a disease or disorder in humans including women of child bearing potential and pediatric patients, in which aldosterone overexposure contributes to the deleterious effects of said disease or disorder, typically and preferably, wherein said disease or disorder is selected from primary and secondary hyperaldosteronism, heart failure, chronic renal failure, hypertension, restenosis, obesity, nephropathy, post-myocardial infarction, renal fibrosis, and coronary heart disease.

Further, the present invention provides for ( ?)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine as well as the phosphate salt thereof, preferably the (R)-(+)- 5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l ,5-a]pyridine dihydrogen phosphate, typically and preferably having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%), e.g. 99.9%) for use in a method of the treatment of a disease or disorder, wherein said disease or disorder is selected from primary and secondary hyperaldosteronism, heart failure, chronic renal failure, hypertension, restenosis, obesity, nephropathy, post-myocardial infarction, renal fibrosis, and coronary heart disease. Further preferably, said method is in particular suited for use in humans including preferably for women of child bearing potential and pediatric patients.

In a further very preferred embodiment and aspect, the present invention provides for provides crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, preferably anhydrous crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%>, e.g. 99.9%, for use in a method of treating a disease or disorder in a human, wherein said disease or disorder is selected from primary and secondary hyperaldosteronism, heart failure, chronic renal failure, hypertension, restenosis, obesity, nephropathy, post-myocardial infarction, renal fibrosis, and coronary heart disease, wherein preferably said human is a woman of child bearing potential or a pediatric patient.

In a further very preferred embodiment and aspect, the present invention provides for provides crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, preferably anhydrous crystalline (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, having an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%>, e.g. 99.9%, for use in a method of treating a disease or disorder in a human, wherein said disease or disorder is selected from primary and secondary hyperaldosteronism, heart failure, chronic renal failure, hypertension, restenosis, obesity, nephropathy, post-myocardial infarction, renal fibrosis, and coronary heart disease, wherein preferably said human is a woman of child bearing potential or a pediatric patient, and wherein said (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate inhibits aromatase activity in the cell-free human recombinant aromatase enzyme assay described in Example 8 with an IC₅₀ of 700 nM or more, preferably 750 nM or more, more preferably 800 nM or more, more preferably 850 nM or more, more preferably 900 nM or more, more preferably 950 nM or more, more preferably 1000 nM or more, more preferably 1050 nM or more, more preferably 1 100 nM or more, more preferably 1150 nM or more, more preferably 1200 nM or more, more preferably 1250 nM or more, more preferably 1300 nM or more, more preferably 1350 nM or more, more preferably 1400 nM or more, more preferably 1450 nM or more, more preferably 1500 nM or more, more preferably 1550 nM or more, most preferably at least 1600 nM, e.g. 1610 nM or 1620 nM or 1630 nM or 1640 nM or at least 1650 nM.

In a further aspect, the present invention provides for a process for preparing a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine and a pharmaceutically acceptable salt thereof, and wherein very preferably said pharmaceutically acceptable salt is the phosphate salt thereof, and further preferably the (R)- (+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l ,5-a]pyridine dihydrogen phosphate. The inventive processes comprise the steps of: (i) reacting racemic 5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine with a (-)-0,0'-acylated L-tartaric acid, in particular (-)-0,0'-dibenzoyl-L-tartaric acid to form the diastereomeric (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine dibenzoyl-L-tartrate salt; and (ii) recrystallizing at least once the tartrate salt obtained in step i; and (iii) liberating the free base (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine by adding a base to a solution of said tartrate salt obtained in step ii; and optionally (iv) forming a pharmaceutically acceptable salt by reacting said free base with an acid, preferably with phosphoric acid (H₃PO₄). In one embodiment, said (i) reacting racemic 5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l ,5-a]pyridine with a (-)-0,0'-acylated L-tartaric acid, in particular (-)- 0,0'-dibenzoyl-L-tartaric acid to form the diastereomeric (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l ,5-a]pyridine dibenzoyl-L-tartrate salt is effected in an alcoholic solution, preferably in a solution of ethanol, at a temperature of below about 50°C, preferably of below about 45°C, and further preferably of below about 40°C. In one embodiment, said (ii) recrystallizing at least once the tartrate salt obtained in step (i) is effected in an aqueous- alcoholic solution, preferably in an aqueous ethanolic solution, wherein preferably the ratio of water:ethanol is of about 2.4: about 10.

In one embodiment, the process for preparing a compound selected from (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine and a pharmaceutically acceptable salt thereof of the invention does not comprise a step of chiral resolution of 5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine (fadrozole) by means of chiral preparative HPLC, wherein preferably said process for preparing a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine and a pharmaceutically acceptable salt thereof of the invention does not comprise a step of chiral resolution of 5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine (fadrozole) by means of chiral HPLC. Such step of chiral resolution by means of chiral HPLC can typically comprise (i) repetitive chiral HPLCs on low capacity columns or (ii) preparative HPLC on high capacity column.

In a preferred embodiment, the process of the invention yields (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine and its pharmaceutically acceptable salts thereof, in particular the phosphate salt thereof, further preferably the (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l ,5-a]pyridine dihydrogen phosphate, with an ee of the (R) form higher than or equal to 97%, preferably higher than or equal to 98%, more preferably higher than or equal to 99%, and again more preferably higher than or equal to 99.5%, again more preferably higher than or equal to 99.8%, e.g. 99.9%.

In a further preferred embodiment, the process of the invention yields (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine and its pharmaceutically acceptable salts thereof, in particular the phosphate salt thereof, further preferably (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l ,5-a]pyridine dihydrogen phosphate, wherein said (i?)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine and its pharmaceutically acceptable salts thereof inhibit aromatase activity in the cell-free human recombinant aromatase enzyme assay described in Example 8 with an IC₅₀ of of 700 nM or more, preferably 750 nM or more, more preferably 800 nM or more, more preferably 850 nM or more, more preferably 900 nM or more, more preferably 950 nM or more, more preferably 1000 nM or more, more preferably 1050 nM or more, more preferably 1 100 nM or more, more preferably 1 150 nM or more, more preferably 1200 nM or more, more preferably 1250 nM or more, more preferably 1300 nM or more, more preferably 1350 nM or more, more preferably 1400 nM or more, more preferably 1450 nM or more, more preferably 1500 nM or more, more preferably 1550 nM or more, most preferably at least 1600 nM, e.g. 1610 nM or 1620 nM or 1630 nM or 1640 nM or 1650 nM or more.

The inventive processes, thus, utilize crystallization to obtain ( ?)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine and its pharmaceutically acceptable salts thereof, and very preferably its phosphate salt thereof, and again further the (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l ,5-a]pyridine dihydrogen phosphate, in exceptional high chiral purity for commercial pharmaceutical use. On a commercial scale, crystallization is much more advantageous being more economical than chromatographic resolution by allowing for larger batch preparation, less expensive equipment and facilities, and not requiring specialized expertise.

In one aspect, there is provided a pharmaceutical composition comprising (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine or a pharmaceutically acceptable salt thereof, in particular a phosphate salt, more preferably the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l ,5-a]pyridine dihydrogen phosphate, as described herein in admixture with at least one pharmaceutically acceptable excipient.

In one embodiment, said pharmaceutical composition is provided in the form of tablets, pills, dispersible granules, cachets, capsules, powders, lozenges, suppositories or retention enemas. EXAMPLES

Equipment, Materials and Methods

Specific Optical Rotation fajn

The Specific Optical Rotation [α]ο measurements were performed in solution using the sodium D-line at 589.3 nm of a standard Perkin Elmer Polarimeter 343. For the measurement 1 gram of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine-dihydrogen- phosphate was dissolved in 100 ml of the respective solvent and this solution was transferred in an optical cuvette of 1 decimeter length. The measurement was done at a temperature of 20°C or 25°C, respectively. The Specific Optical Rotation [α]ο is calculated by the formula 100 x a / (1 x c) where: a = observed rotation in degrees; 1 = cell path length in decimeters; c = concentration in grams per 100 ml.

Elemental Analysis

Elemental analysis was performed on standard equipment (e.g. vario EL cube elemental analyzer) and the values for carbon, hydrogen and nitrogen were determined.

Chiral HPLC

The chiral HPLC was performed on an Agilent 1100 series LC22 instrument with the following column specifications and conditions:

Column: Chiralpack AD-H, granulometry: 5 μιη, 250x4.6 mm; n° ADH0CE-TF087

Mobile phase: Ethanol + 0.1% diethylamine (DEA)

Detector wavelength: 230 nm

Oven temperature: 25 °C

Flow rate: 0.5 mL/min

Injection volume: 5

Sample preparation: 0.5 mg/mL in Ethanol + 0.1% DEA XRPD

The X-ray powder diffraction studies were performed using a Bruker AXS D2 PHASER in Bragg-Brentano configuration. Using a Cu anode at 30kV, 10 mA; sample stage standard rotating; monochromatisation by a Κβ-filter (0.5% Ni). Slits: fixed divergence slits 1.0mm (=0.61°), primary axial Soller slit 2.5°, secondary axial Soller slit 2.5°. Detector: Linear detector LYNXEYE with receiving slit 5° detector opening. The standard sample holder (0.1 mm cavity in (510) silicon wafer) had a minimal contribution to the background signal. Measurement conditions: scan range 5 to 45° 2theta, sample rotation 5 rpm, 0.5s/step, 0.010°/step, 3.0mm detector slit; and all measuring conditions were logged in the instrument control file. As system suitability, corundum sample A26-826-S (NIST standard) was measured daily.

The software used for data collection was Diffrac. Commander v2.0.26. Data analysis was done using Diffrac.Eva vl .4. No background correction or smoothing was applied to the patterns. Single crystal X-ray analysis

Single crystals of (i?)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine- dihydrogen-phosphate were grown using a n-propanol/water mixture as solvent. A suitable single crystal was taken out of the mother liquor, immediately coated with high viscosity oil, cut to size and mounted on a Mitagen Micro loop and shock frozen to 150 K. The measurement was performed on a Bruker D8 Quest instrument with MoKa radiation, using φ- scans and ω-scans. The molecular structure was subsequently solved by direct method (SHELXT software). All non-hydrogen atoms were refined with anisotropic temperature factors. On the completed model, Bijovet analysis was performed to determine the absolute configuration.

TGA/DSC

The thermogravimetric analysis and differential scanning calorimetry (TGA/DSC) studies were performed using a Mettler Toledo TGA/DSCl STARe System with a 34-position auto sampler. The samples were made using AI crucibles (40 μί; pierced). Typically 5 - 10 mg of sample was loaded into a pre-weighed Al crucible and was kept at 30°C for 5 minutes, after which it was heated at 10°C/min from 30°C to 350°C. A nitrogen purge of 40 ml/min was maintained over the sample. The software used for data collection and evaluation was STARe Software vl2.10 build 5937. No corrections were applied to the thermogram. DSC

The DSC studies were performed using a Mettler Toledo DSC1 STARe System. The samples were made using Al crucibles (40 μί; pierced). Typically 1 - 8 mg of sample was loaded onto a pre-weighed Al crucible and was kept at 30°C for 5 minutes, after which it was heated at 10°C/min from 30°C to 350 °C and kept at 350°C for 1 minute. A nitrogen purge of 40 ml/min was maintained over the sample. As system suitability check Indium and Zinc were used as references. The software used for data collection and evaluation was STARe Software vl2.10 build 5937. No corrections were applied to the thermogram.

DVS

The Dynamic Vapour Sorption (DVS) studies were performed using a Surface Measurement Systems Ltd. DVS-1 No Video. The sample was loaded into a balance pan, typically 20-30 mg, and equilibrated at 0% RH. After the material was dried, the RH was increased with 10% per step for 1 hour per increment, ending at 95% RH. After completion of the sorption cycle, the sample was dried using the same method. The software used for data collection was DVSWin v3.01 No Video. Data analysis was performed using DVS Standard Analysis Suite v6.3.0 (Standard).

Solubility

The solubility was determined using the shake- flask method; the solubility was visually determined at 20°C. The listed solvents were added stepwise to 10 mg of compound, with 15 minutes in between additions, until complete dissolution was obtained or a solubility of less than 0.05 mg/ml was reached.

High Throughput Experimentation

High throughput experimentation was performed in well-plate format using a Freeslate Core Module 2 in crystallization configuration equipped with a Julabo FPSO for temperature control of the cooling crystallization experiments.

Solid Dispense System

Solids were dispensed using a Freeslate Core Module Protege Solid Dispense System in classic and SV-hopper configuration with a Sartorius balance. Hoppers that were used were 25 ml classic hoppers with 8 mm valve size and 4 to 3 mm funnel size, 10 ml classic hoppers with 8 mm valve size and 4 to 3 mm funnel size and SV hoppers with standard 4 ml glass vials.

Racemic 5-(p-cyanophenyl)-5, 6, 7, 8-tetrahydroimidazo[l,5-a] pyridine

The title compound (fadrozole) may be prepared e.g., according to the procedure described by L. J. Browne et al. (J. Med. Chem. 1991, 34, 725.) or obtained by commercial suppliers such as Sigma-Aldrich. EXAMPLE 1

Diastereomeric salt screening with racemic 5-(p-cyanophenyl)-5,6,7,8- tetr ahydroimidazo [ 1 ,5-a] pyridine

100 mg (1.0 eq) of the title compound were dissolved in isopropanol, followed by addition of a solution of chiral acid (0.5 eq) in isopropanol (0.5 mL). The result of the screening is summarized in Table 2.

Table 2 - Summary of enantioselective salt crystallization experiments

EXAMPLE 2

Salt screening with (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetr ahydroimidazo [1,5-a] pyridine

General Procedure: The title compound (free base) was dissolved in ethanol (at 100 g/L) at 35 °C, followed by addition of the acid at the same temperature. The resulting mixture was cooled to 10 °C at a cooling rate of -20 °C/h and the precipitate (if any) was filtered off, washed with ethanol and dried under reduced pressure (at 50 °C).

The result of the salt screening is summarized in Tables 3 to 5. Table 3 - Summary of salt screening experiments with ethanol as solvent

Salt forming acid Stoichiometry (eq) Result fumaric acid 1:1 oil

tartaric acid 1:1 solid

sulfuric acid 1:1 oil

phosphoric acid* 1:1 solid

adipic acid 1:1 oil

glucuronic acid* 1:1 no salt isolated glutaric acid 1:1 oil

malic acid 1:1 oil

malonic acid 1:1 oil

fumaric acid 1:2 solid

tartaric acid 1:2 solid

adipic acid 1:2 oil

glutaric acid 1:2 oil

malic acid 1:2 oil

malonic acid 1:2 oil

slurry

Table 4 - - Summary of salt screening experiments with methanol as sc

Counter ion Stoichiometry (eq) Result fumaric acid 1:1 solid

tartaric acid 1:1 oil

sulfuric acid 1:1 oil

phosphoric acid* 1:1 solid

adipic acid 1:1 oil

glucuronic acid* 1:1 oil

glutaric acid 1:1 oil

malic acid 1:1 oil

malonic acid 1:1 oil

fumaric acid 1:2 solid

tartaric acid 1:2 oil

adipic acid 1:2 counter ion salt glutaric acid 1 :2 oil

malic acid 1 :2 oil

malonic acid 1 :2 oil

* slurry

With the phosphate salt, the tartrate salt and the fumarate salt that were obtained as solids, a solid state characterization according to Table 5 was performed.

Table 5 - Solid state characterization

EXAMPLE 3

Preparation of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium [ 1 ,5-a] pyridine dihydrogen phosphate (Crystalline Form I)

Step 1: Preparation of (R)-(+)-5-(p-cyanophenyl)-5,6, 7,8-tetrahydroimidazolium[l,5- a ] pyridine dibenzoyl-L-tartrate

In a 10 L reactor were loaded at 20°C racemic 5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine (328 g, = 1.0 eq) and ethanol (2.3 L). The mixture was heated to 40°C then a solution of (-)-0,0'-dibenzoyl-L-tartaric acid (276.4 g, 0.5 eq) in ethanol (1 L) was added. The mixture was maintained at 40°C for 1 h, then cooled to 20°C over a period of 2 h, maintained for 1 h at this temperature, then cooled to 10°C over a period of 0.5 h and finally maintained at 10°C overnight. The precipitate was subsequently filtered off and the filter cake was washed with cold (0°C) ethanol (1 L) to afford the title compound as a white humid powder (485 g, = 413.7 g estimated dry, by loss on drying, 48.4%, ee = 87%).

Step 2: RecrystaUization of (R)-(+)-5-(p-cyanophenyl)-5,6, 7,8-tetrahydroimidazolium[l,5- a ] pyridine dibenzoyl-L-tartrate

In a 10 L reactor were loaded at 20°C (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dibenzoyl-L-tartrate (485 g, ee = 87%, = 413.7 g estimated dry, by loss on drying, = 1.0 eq) obtained from step 1, ethanol (10 L, 24 V) and water (2.4 L, 6V). The resulting mixture was heated to reflux, whereupon a solution was formed. The solution was then cooled to 50°C and maintained at this temperature for 1 h. Subsequently, the mixture was allowed to cool to 10°C over a period of 2 h and then maintained at this temperature overnight. The precipitate was filtered off and the filter cake was washed with cold (0°C) ethanol (1.2 L). The product was dried under reduced pressure at 40°C to afford the title compound as a white powder (294.8 g, 71%, single enantiomer).

Enantiomeric Excess: >99.9% as determined by HPLC

Step 3: Preparation of (R)-(+)-5-(p-cyanophenyl)-5,6, 7,8-tetrahydroimidazo[l,5-a]pyridine (free base)

In a 2 L reactor were loaded (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dibenzoyl-L-tartrate (177 g, single enantiomer) obtained from step 2 and dichloromethane (1.77 L, 10 V). Then, a solution of Na₂C0₃ (71g, 2.2 eq) in water (875 mL) was added. After 0.25 h stirring at room temperature, the mixture was decanted. The liquid phases thus obtained were limpid and the aqueous phase had a pH of 8-9. The organic phase was washed with water (2x875 mL) and then concentrated under vacuum. The residue was dissolved in ethanol and again concentrated under vacuum to afford the title compound (70 g, quant.) as an oil which solidified upon standing.

Step 4: (R)-(+)-5-(p-cyanophenyl)-5,6, 7 8-tetrahydroimidazoliumfl ,5-aJpyridine dihydrogen phosphate

In a 1 L reactor were loaded (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5- ajpyridine (94 g, 1.0 eq) and ethanol (564 mL) and the mixture was heated to 35°C. The solution was filtered and the reactor was rinsed with ethanol (94 mL). A solution of H₃PO₄ (97 g, 85%) wt/wt in H₂0) in ethanol (235 mL) was added at the same temperature, rinsing with ethanol (47 mL). After stirring for 1 h at 35 °C, the mixture was cooled to 10 °C (at a rate of -20°C/h) and kept at this temperature for 10 h. The resulting solid was filtered off and the filter cake was washed with cold (10°C) ethanol (3><94 mL). After drying at 50°C under reduced pressure, the title compound was obtained as a white, crystalline, free flowing powder (100 g, 74%).

XRPD: see Fig. 1 and Table 1

Melting Point: 189°C as determined by TGA/DSC (Fig. 2).

Enantiomeric Excess: >99.9% (Fig. 3). The chiral HPLC for the determination of the enantiomeric excess of the preparation featured a retention time (tr) of 14.459 min for the R- (+)-enantiomer and 9.814 Min for the S-(-)-enantiomer.

Absolute configuration: R-(+)- on carbon 5 as determined by single crystal X-ray.

Specific optical rotation (CH₃CN:H₂0 1 : 1 (v/v)): [a]_D ²⁰ = +98.1

Hygroscopicity: 1.0% at >90% relative humidity (RH) as determined by DVS. Water uptake is reversible and crystalline form does not change upon DVS treatment (Figs. 4 to 6). Mass loss upon heating up until 225°C is 1.4% as determined by TGA/DSC (Fig. 2). The crystals of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate were further characterized by their elemental analysis, which is in accordance with the values calculated from the molecular formula Ci₄Hi₆N₃0₄P (MW:321.27): C 52.4 %; H 5.1 %; N 13.03 %.

EXAMPLE 4

Preparation of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium [ 1 ,5-a] pyridine- chloride from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydro-imidazolium [ 1 ,5-a] pyridine dihydrogen phosphate via the free base

(R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydro-imidazolium[l,5-a]pyridine dihydrogen phosphate (1000 mg, 3.11 mmol,) as prepared in Example 3 was suspended in Et₂0 (30 ml) and extracted with saturated aqueous NaHC0₃ solution (30 ml). The aqueous layer was extracted with diethyl-ether (2 x 20 ml) and the combined organic layers were washed with brine (10 ml) and distilled water (10 ml), dried over Na₂S0₄, filtered and evaporated to obtain the free base (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine as a white solid which was dried in vacuum over night at 50°C (530 mg).

Melting point: 101-102 °C; Specific optical rotation (ethanol): [α]ο²⁵ = +127.3;

The so obtained (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine (100 mg, 0.447 mmol, 1 eq) was dissolved in methylene chloride (2.2 ml) and HC1 (2 M in diethylether, 0.34 ml, 0.76 mmol, 1.5 eq) was added and the mixture was stirred for 30 minutes at RT, then evaporated and dried under vacuum at 80 °C. (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydro-imidazolium[l,5-a]pyridine chloride was isolated as a crystalline solid. Melting point: 240-243 °C; Specific optical rotation (ethanol): [a]_D ²⁰ = +104.8; Specific optical rotation (CH₃CN:H₂0 1 : 1 (v/v)): [a]_D ²° = +124.4.

EXAMPLE 5

Hygroscopicity of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydro-imidazolium[l,5- a]pyridine-dihydrogen phosphate compared to (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydro-imidazolium[l,5-a]pyridine-chloride

100 mg samples of the two crystalline salts were stored in open flasks for 24 hours side by side at room temperature in unconditioned ambient air and weight measurements occurred at time 0 and after 24 hours (Table 6). (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydro- imidazolium[l,5-a]pyridine dihydrogen phosphate shows a weight increase of 0.57% and is considered to be non-hygroscopic as compared to the significant hygroscopicity of the corresponding (i?)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine chloride evidenced by the 13.1% weight increase.

Table 6. Comparison of hygroscopic properties

EXAMPLE 6 Shake-flask solubility study of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a] pyridine dihydrogen phosphate

A shake-flask solubility study was performed on the material according to U.S. Pharmacopoeia (USP) specifications. A set of pharmaceutically accepted process solvents with different functional groups has been used to determine the shake-flask solubility. The solvents were allowed to evaporate at 0-100 mbar at room temperature overnight. All solids have then been subsequently analysed using XRPD. The results of this study can be found in Table 7 below. Table 7. Shake-flask solubility results of the different batches

The material is very soluble in water, freely soluble in methanol and acetic acid, very slightly soluble in ethanol and practically insoluble in the other tested solvents. In Table 8 the XRPD results of the performed measurements on either the solids of the slurry or the solids of the solution after evaporation are given.

Table 8. XRPD results after solubility determination

Sample code XRPD

DF1181-5-S1 Form I - Conform starting material

DF1181-5-S2 Form I - Conform starting material

DF1181-5-S3 Form I - Conform starting material

DF1181-5-S4 Form I - Conform starting material

DF1181-5-S5 Form I - Conform starting material

DF1181-5-S6 Form I - Conform starting material

DF1181-5-S7 Form I - Conform starting material

DF1181-5-S8 Form I - Conform starting material

DF1181-5-S9 Form I - Conform starting material

DF1181-5-S10 Form I - Conform starting material

DF1181-5-S11 Amorphous No new polymorphic form was obtained after evaporation of the solvents, except for acetic acid (amorphous), confirming the exceptional stability of crystalline form I.

EXAMPLE 7

Polymorph study on (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5- a] pyridine dihydrogen phosphate

Solvents and co-solvents were added in different ratios. The different ratios were 100% solvent and 0%> co-solvent, 80%> solvent and 20%> co-solvent, 60%> solvent and 40%> co- solvent, 40%) solvent and 60%> co-solvent, 20%> solvent and 80%> co-solvent and 5% solvent and 95%) co-solvent, subsequently. Table 9 shows the layout of the study conditions and the respective XRPD conclusions on polymorphic forms.

Table 9. Layout of the 96-well polymorph study master plate

The starting material was dispensed (30 mg) in a 96-well plate ("master plate") using Freeslate CM Protege solid dispense system. After solid dispense the well plate was transferred to the Freeslate Core Module 2 for liquid dispenses (solvent + co-solvent total = 800 μί). The master plate was allowed to stir for 2h at 50°C. An aliquot of the samples in the master plate was transferred to a cooling crystallization plate via a hot filtration plate. The samples in the cooling plate were then allowed to cool from 50°C to 10°C over a period of 5 hours using a cubic cooling rate. None of the wells contained solids, so to simulate evaporative crystallization the solvents were allowed to evaporate at 0-100 mbar at RT. All of the formed solids were analysed using XRPD. All diffracto grams were compared with the reference diffractogram as outlined in Fig. 1 by overlaying the respective diffractograms (Fig. 6). In this study, only one polymorph of the title compound, form I, could be identified having the described very beneficial and surprising properties. This finding seems to confirm that crystallization is not only a function of salt selection but also of crystallization process conditions leading to the inventive form I of the (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate (P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor); Handbook of Pharmaceutical Salts: Properties, Selection, and Use, 2nd Revised Edition, March 2011 , Wiley- VCH, ISBN: 978-3-90639-051-2).

EXAMPLE 8

Assessment of aromatase and aldosterone synthase inhibition by (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a] yridine dihydrogen phosphate

Human NCI-H295R Cell Assay for Aldosterone Synthase (CYP11B2 and Aromatase (CYP19 Activities

NCI-H295R cells, a continuous cell line derived from an invasive primary adrenocortical carcinoma were obtained from CLS cell line services GmbH (catalog No. 300483). Because NCI-H295R cells produce both aldosterone and estradiol, they enable measuring aldosterone synthase activity and aromatase activity under identical conditions. Prior to being used for the assays the cells were maintained in DMEM/Ham's medium with 15 mM HEPES and 1.2 g NaHC0₃ supplemented with 5% steroid- free serum replacement, Panexin BMM (PAN Biotech, Aldenbach, Germany; cat. no. P04-9515A2), 1% Penicillin/Streptomycin, 1.25 % L-Glutamine, and 6.25 μg/ml insulin, 6.25 ng/ml selenium, 5.35 μg/ml linoleic acid and 1.25 mg/ml bovine serum albumin. The cells were maintained at 37°C under an atmosphere of 95 % air/5 % C0₂. For the assays the cells were sub-cultured at a density of 5 x 10⁵ cells per well in 24-well plates and grown until 50-60% confluency (48 h). The growth medium then was replaced with 500 μΐ serum-free DMEM: Ham's F12 containing the test compound dissolved in ethanol/water 1 : 1 (v/v) so that the final concentration in the assay consisted of 0.5% ethanol. Six concentrations were evaluated, and control samples with no compound were supplemented with 0.5% ethanol. The cells with compound were incubated at 37°C under 95% air/5% C0₂ for 6h. After which the supernatant was removed and stored at -20°C until analysis. After the supernatant was removed the cells were evaluated to assure viability by optical evaluation utilizing phase contrast microscopy examination for morphological changes and by the resazurin method which measures the conversion of resazurin into a fluorescent end product resorufm. Non-viable cells lack the metabolic capacity to make the conversion. The conversion was quantified by measuring the fluorescence at 544 nm /590 nm (extinction / emission) respectively using a Wallac 1420 Multiple Counter Victor Fluorometer/Luminator (Perkin Elmer, Wlatham, MA).

Quantification of aldosterone concentration as a measure of aldosterone synthase activity was accomplished by LC-MS as follows. Prior to analysis acetonitrile was used to precipitate the sample protein and following centrifugation the particle free supernatant was subject to LC-MS. The HPLC system consisted of an Accela U-HPLC pump and Accela Open auto sampler (Thermo Fisher Scientific, Waltham, MA). Mass spectrometry was performed using a Q-Exactive MS (Orbitrap) equipped with a heated electrospray (H-ESI) interface connected to a PC running the standard Xcalibur software 2.2 (Thermo Fisher Scientific, Waltham, MA). The LC was performed in the gradient mode using acetonitrile with 0.1 % formic acid (solvent A) and aqueous 0.1 % formic acid solvent B. The pump flow rate was set to 600 μΐ/min, and separation was performed on a Kinetex Phenyl-Hexyl 2.6 μιη, 50 x 2.1 mm analytical column (Phenomenex, Germany) with a C6-Phenyl, 4x 2.0 mm ID pre-column for quantification. As MS tune file a generic tune file was used and as a lock mass for internal calibration the [M+H]⁺ ion of the disooctyl phthalate (m/z 391.28492) present in the solvent system was used. Full MS-SIM analysis (m/z: 250-400) was applied with the mass resolution of the Orbitrap™ set to 35,000. The sample injection volume was 20 μΐ for all samples. The results were displayed as ng/ml and inhibition of aldosterone production was expressed as per cent inhibition relative to untreated controls i.e., in absence of any inhibitor (Table 10). IC₅₀ values were calculated using linear interpolation using the concentrations of test compound and the corresponding percentage inhibition that are immediately above and below 50%) as illustrated below: IC₅o = (50% - Lowi_nh%)/(Highi_nh% - Low_in]l%) x (High_conc- Low_conc) + Low_conc where "inh" is inhibition and "cone" is concentration.

Table 10. Inhibition of aldosterone production by (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a] pyridine dihydrogen phosphate in NCI-H295R cells.

aHigh_conc = the lowest concentration of the test item that inhibits by at least 50% (10 nM) ^bLow_conc = the highest concentration of the test item that inhibits less than 50% (1 nM) ^cHighi_n = percent inhibition achieved at the High_conc of the test item (60.8%>)

dLowi_nh = percent inhibition achieved at the Low_conc of the test item (8.7%)

IC₅₀ = (50%-8.7%)/(60.8% - 8.7%) x (10 nm - 1 nM) + 1 nM = 8.1 nM

IC₅₀ = 8.1 nM for inhibition of aldosterone production (aldosterone synthase activity)

Aromatase activity was measured by quantification of the estradiol concentration in the supernatant from incubation of NCI-H295R cells as described above for determination of aldosterone synthase activity except that much higher concentrations of the inhibitor, as indicated below were used to obtain an IC50. Quantification of estradiol concentration was accomplished using a 17-beta-estradiol ELISA kit from IBL-Hamburg (Hamburg, Germany) according to the manufacturer's instructions. A standard curve was generated by plotting the absorbance of each reference standard (y-axis) against the corresponding log concentration (x-axis). The absorbance of each sample was used to determine the corresponding values by interpolation from the standard curve using GraphPad Prism 5.04 software (GraphPad Software Inc., San Diego, CA). An IC₅₀ was calculated using the formula described above for the aldosterone synthase data disclosed in Table 11. Table 11. Inhibition of estradiol production by (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a] pyridine dihydrogen phosphate in NCI-H295R cells.

High_conc = the lowest concentration of the test item that inhibits by at least 50% (10 μΜ) ^bLow_conc = the highest concentration of the test item that inhibits less than 50% (1 μΜ) ^cHighi_n = percent inhibition achieved by the High_conc of the test item (68.6%>)

dLowi_nh = percent inhibition achieved by the Low_conc of the test item (29.1%)

IC₅₀ = (50% - 29.1%)/(68.6% - 29.1%) x (10 μΜ - ΙμΜ) + 1 μΜ = 5.76 μΜ or 5760 ηΜ IC₅o = 5760 ηΜ for inhibition of estradiol production (aromatase activity) Cell- free Human Recombinant Aromatase Assay

Aromatase (CYP19) activity was measured using a human CYP19 assay kit (Corning®, Corning, NY; Product #456260) according to the manufacturer's instructions. The assay system utilized a recombinant human enzyme, a fluorometric substrate MFC ( 7-methyl-4- trifluoro-methyl-Coumarin), and an NADPH regenerating system consisting of glucose-6- phosphate dehydrogenase, NADP⁺, and glucose-6-phospahate. For determining the concentrations of the test compounds which inhibited the enzyme activity by 50% (IC₅₀) eight test concentrations were tested. The test compounds were dissolved in ethanol/water 1 : 1 (v/v) so that the final ethanol concentration in the assay was 1%. The test compounds at various concentrations along with the NADPH regenerating system were added to 96-well plates. After a 10 min pre-incubation the reaction was started by the addition of pre-warmed enzyme substrate mix and allowed to continue for an additional 30 min at 37° C. The reaction was then stopped by the addition of a solution of 80%> acetonitrile and 20%> 0.5M Tris base (stop solution). To control for background fluorescence, blank wells (containing no test samples) were also assayed but these wells had the stop solution added prior to the addition of the enzyme substrate mixture. The fluorescent product formed, 7-hydroxy-4-triflouro-methyl- Coumarine (HFC) was detected using a Wallac 1420 Multiple Counter Victor Fluorometer/Luminator (Perkin Elmer, Wlatham, MA). The wave lengths for excitation and emission were 405 and 535 nm, respectively. The data was compiled with standard software Wallac 1420 Manager 3.0. In addition to subtraction of the blank well samples as indicated above, each test substance was pre-tested for auto-fluorescence. For this purpose the NADPH generating system (co factor mix) and the enzyme/substrate-mix were replaced by a comparable mixture of control protein, assay buffer, and test compound solvent. These control samples were then pre-incubated and assayed and as described above. Three independent determinations of the IC₅₀ were made from line of best fit plots of % inhibition versus inhibitor concentration (Table 12).

Table 12. Inhibition of human recombinant aromatase activity by (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium [ 1 ,5-a] pyridine dihydrogen phosphate.

EXAMPLE 9 Assessment of stability data for (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazolium[l,5-a] pyridine dihydrogen phosphate

Long-term stability data relevant and important for regulatory considerations have been measured. Hereto, various tests as indicated in below Tables 13 to 15 have been conducted at either 25°C and 60%RH (Table 13), at 30°C and 65%RH (Table 14), and at 40°C and 75%RH (Table 15) each test at various time points (initial, after 1 , 3 and 6 months or even longer).

It has been shown that (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l ,5- ajpyridine dihydrogen phosphate is very stable over a long and extended period of time, and that in particular long-term stability has been shown with respect to purity, water content and thus hygroscopicity as well as chiral purity under the assessed stability conditions and time periods. Moreover, and importantly, no change of polymorphism was observed at neither assessed condition and time periods.

Table 13. Stability data at stability conditions 25°C/60%RH for (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium [ 1 ,5-a] pyridine dihydrogen phosphate.

Table 14. Stability data at stability conditions 30°C/65%RH for (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium [ 1 ,5-a] pyridine dihydrogen phosphate.

Table 15. Stability data at stability conditions 40°C/75%RH for (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a] pyridine dihydrogen phosphate. Test Initial 1 month 3 months 6 months

Appearance White White powder White powder White powder powder

Assay by HPLC, 99.9 99.7 100.2 99.2 anhydrous, solvent free

Purity by HPLC 99.87 99.80 99.79 99.88

Water content 0.3 0.3 0.5 0.3

Chiral Purity >99.5 >99.5 >99.5 >99.5

Polymorph by XRPD Conform to Conform to Conform to Conform to initial initial initial initial

Claims

A compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5- ajpyridine and a pharmaceutically acceptable salt thereof, wherein said compound has an enantiomeric excess of the (R) form higher than or equal to 97%.

The compound of claim 1, wherein said compound inhibits aromatase activity in the cell- free human recombinant aromatase enzyme assay with an IC₅₀ of 700 nM or more, preferably 1000 nM or more, and more preferably 1500 nM or more.

The compound of claim 1 or claim 2, wherein said compound inhibits aldosterone synthase in the NCI-H295R adrenal cell assay with an IC₅₀ of 100 nM or less, preferably 50 nM or less, and more preferably 10 nM or less.

The compound of any one of the claims 1 to 3, wherein said compound has a selectivity for aldosterone synthase over aromatase of 50 or more, preferably of 100 or more, most preferably of 700 or more; wherein said selectivity is determined by the ratio of the IC₅₀ values for inhibition of aromatase and aldosterone synthase; wherein the IC₅₀ values for inhibition of aldosterone synthase and aromatase are both measured in the NCI-H295R adrenal cell assay.

The compound of any one of the claims 1 to 4, wherein said compound is (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate.

The compound of any one of the claims 1 to 5, wherein said pharmaceutically acceptable salt is crystalline.

The compound of any one of the claims 1 to 6, wherein said pharmaceutically acceptable salt is anhydrous.

The compound of any one of the claims 1 to 7, wherein said pharmaceutically acceptable salt is non-hygroscopic.

The compound of any one of the claims 5 to 8, wherein said (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate has a melting point of equal or between 184 °C to 193 °C, and wherein preferably said (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate has a melting point of equal or between 188 °C to 190 °C as determined by thermogravimetry analysis/differential scanning calorimetry (TGA/DSC).

10. The compound of any one of the claims 5 to 9, wherein said (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate is a crystalline form I of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate, wherein said crystalline form I has an X-ray powder diffraction pattern comprising the following 2Θ values measured using CuKa radiation: 19.504; 21.919 and 24.159, wherein each peak may vary by ± 0.5, or preferably by ± 0.2 degrees.

11. The compound of claim 1, wherein said compound is (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8 -t etr ahydroimidazo [ 1 , 5 - a] pyridine .

12. (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate.

13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11 or (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate according to claim 12 in admixture with at least one pharmaceutically acceptable excipient, and wherein preferably said pharmaceutical composition is in the form of tablets, pills, dispersible granules, cachets, capsules, powders, lozenges, suppositories or retention enemas.

14. The compound according to any one of claims 1 to 11; (R)-(+)-5-(p-cyanophenyl)- 5,6,7,8-tetrahydroimidazolium[l,5-a]pyridine dihydrogen phosphate according to claim 12 or the pharmaceutical composition according to claim 13 for use in a method of the treatment of preferably humans including premenopausal female and pediatric patients with disease or disorder in which aldosterone over-exposure contributes to the deleterious effects of said disease or disorder, and wherein preferably said disease or disorder is selected from primary and secondary hyperaldosteronism, heart failure, chronic renal failure, hypertension, restenosis, obesity, nephropathy, post-myocardial infarction, renal fibrosis, and coronary heart disease and wherein further preferably said disease or disorder is selected from primary and secondary hyperaldosteronism. Process for preparing a compound selected from (R)-(+)-5-(p-cyanophenyl)-5, 6,7,8- tetrahydroimidazo[l,5-a]pyridine and a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 comprising the steps of:

i. reacting racemic 5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine with (-)-0,0'-dibenzoyl-L-tartaric acid to form the diastereomeric (R)-(+)-5-(p- cyanophenyl)-5,6,7,8-tetrahydroimidazo[l ,5-a]pyridine dibenzoyl-L-tartrate salt; and

ii. recrystallizing at least once the tartrate salt obtained in step i; and

iii. liberating the free base (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5- ajpyridine by adding a base to a solution of the tartrate salt obtained in step ii; and optionally

iv. forming a pharmaceutically acceptable salt by reacting said free base with an acid, wherein preferably said acid is phosphoric acid (H₃PO₄).